Nav: Home

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 22, 2018

BIRMINGHAM, Ala. - In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

The regression seen in this combination therapy of temozolomide and the inhibitor SLC-0111 -- which targets the enzyme carbonic anhydrase 9, or CA9 -- was greater than that seen with either SLC-0111 or temozolomide alone, says research leader Anita Hjelmeland, Ph.D., assistant professor in the Department of Cell, Developmental and Integrative Biology at the University of Alabama at Birmingham.

"Our experiments strongly suggest that a strategy to target a carbonic anhydrase that is increased in glioblastoma, CA9, will improve temozolomide efficacy," Hjelmeland said. "We believe the drug combination could improve patient outcomes in glioblastomas sensitive to chemotherapy."

Glioblastoma is the most common primary brain tumor seen in adults. Half of the tumors recur less than seven months after undergoing the standard treatment of surgery, temozolomide and radiation. The median survival after diagnosis of this deadly cancer is 12 to 14 months. Thus, new approaches to therapy are urgently needed.

Solid tumors like glioblastoma create microenvironments within and around themselves. A common condition is hypoxia, a shortage of oxygen as the tumor outgrows its blood supply. Tumor cells shift to making their energy through glycolysis, a method of metabolism that does not require oxygen. Glycolysis, in turn, changes the acid-base balance at the tumor -- the extracellular space becomes more acidic and the tumor cell interiors become more alkaline, adapting to this change.

In the face of this hypoxia and acid stress, tumor cells over-produce CA9, a membrane enzyme that converts carbon dioxide and water to bicarbonate and protons. This reaction aids maintenance of the altered acid-base balance in the tumor microenvironment.

Thus, CA9 is a possible therapeutic target, and the inhibitor SLC-0111 shows more than 100-fold specificity against CA9, versus two other forms of human carbonic anhydrases, CA1 or CA2. Furthermore, collaborators on this project have previously shown that SLC-0111 exhibits effectiveness against breast cancer xenografts in animals. SLC-0111 has been tested in Phase I clinical safety trials sponsored by Welichem Biotech Inc. in Canada for patients with advanced solid tumors.

The research team led by Hjelmeland and co-first authors Nathaniel Boyd, Ph.D., and Kiera Walker, both working in Hjelmeland's UAB lab, studied glioma cells in cell-culture that were derived from an aggressive pediatric primary glioblastoma and from an adult recurrent tumor. The researchers also studied the tumor in mice, using the adult recurrent glioblastoma.

One reason for recurrence of glioblastoma is a therapeutically resistant sub-population of glioma cells known as brain tumor initiating cells. Part of the focus of the Hjelmeland team was to look at the effect of the combination therapy on that subset of glioblastoma cells.

The researchers found that the combined treatment with temozolomide and SLC-0111 in cell culture experiments: 1) reduced glioblastoma cell growth, 2) induced arrest of the cell-division cell cycle by creating breaks in DNA, 3) shifted the tumor metabolism and intracellular acid-base balance by decreasing metabolic intermediates, and 4) inhibited enrichment of brain tumor initiating cells.

In experiments with mice, the combined treatment with temozolomide and SLC-0111: 1) delayed tumor growth of a patient-derived, recurrent glioblastoma xenograft implanted beneath the skin of immunocompromised mice, as compared to temozolomide alone, and 2) improved survival of the mice when the xenograft was implanted in the brain, a placement that more closely models glioblastoma in patients.

"Clinical trials in glioblastoma often initiate with patients that have a tumor recurrence, and we have demonstrated in vivo efficacy for SLC-0111 with temozolomide in a recurrent glioblastoma," the researchers wrote in their study, published in JCI Insight. "Therefore, our data strongly suggest the translational potential of SLC-0111 for glioblastoma therapy."

"With funds from the Southeastern Brain Tumor Foundation," Hjelmeland said, "we continue to determine whether there are subtypes of glioblastomas that are most likely to respond to combinatorial therapy.
-end-
Co-authors with Hjelmeland, Boyd and Walker in the paper, "Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo," are Joshua Fried and Bo Xu, M.D., Ph.D., Southern Research, Birmingham, Alabama; James R. Hackney, M.D., UAB Department of Pathology; Paul C. McDonald, Ph.D., and Shoukat Dedhar, Ph.D., BC Cancer Research Centre, Vancouver, British Columbia, Canada; Gloria A. Benavides, Ph.D., and Victor Darley-Usmar, Ph.D., UAB Center for Free Radical Biology; Raffaella Spina, Ph.D., and Eli E. Bar, Ph.D., Case Western Reserve University, Cleveland; Alessandra Audia, Ph.D., and Krishna P. Bhat, Ph.D., MD Anderson Cancer Center, Houston; Sarah E. Scott, Catherine J. Libby, Anh Nhat Tran and Mark O. Bevensee, Ph.D., UAB Department of Cell, Developmental and Integrative Biology; Corinne Griguer, Ph.D., and G. Yancey Gillespie, Ph.D., UAB Department of Neurosurgery; Susan Nozell, Ph.D., UAB Department of Radiation Oncology; Burt Nabors, M.D., UAB Department of Neurology; and Emily Gordon, Ph.D., and Sara J. Cooper, Ph.D., HudsonAlpha Institute for Biotechnology, Huntsville, Alabama.

This work was supported by National Institutes of Health grant CA200085, NS096531, CA1515122, the UAB Brain Tumor SPORE CA151129 Career Development Award, a pilot award from the UAB-HudsonAlpha Center for Genomic Medicine, and startup funds from UAB.

Additional support was provided by NIH grants NS100054, CA160821, CA138517, RR027822-01, NS47466 and AI027767.

Hjelmeland, Gillespie, Nabors, Darley-Usmar, Griguer and Nozell are all members of the UAB Comprehensive Cancer Center, one of the nation's leading cancer research and treatment centers.

University of Alabama at Birmingham

Related Chemotherapy Articles:

Chemotherapy drug may increase vulnerability to depression
A chemotherapy drug used to treat brain cancer may increase vulnerability to depression by stopping new brain cells from growing, according to a new King's College London study out today in Translational Psychiatry.
Sperm changes documented years after chemotherapy
A Washington State University researcher has documented epigenetic changes in the sperm of men who underwent chemotherapy in their teens.
Depressed patients are less responsive to chemotherapy
A brain-boosting protein plays an important role in how well people respond to chemotherapy, researchers report at the ESMO Asia 2016 Congress in Singapore.
Breast cancer study predicts better response to chemotherapy
It is known from previous research that the ER-beta estrogen receptor often has a protective effect.
Personalizing chemotherapy to treat pediatric leukemia
A team of UCLA bioengineers has demonstrated that its technology may go a long way toward overcoming the challenges of treatment for acute lymphoblastic leukemia, among the most common types of cancer in children, and has the potential to help doctors personalize drug doses.
How gut microbes help chemotherapy drugs
Two bacterial species that inhabit the human gut activate immune cells to boost the effectiveness of a commonly prescribed anticancer drug, researchers report Oct.
Molecule prevents effect of chemotherapy
For the last three years the research team has been working on the development of a so-called biomarker to predict treatment effectiveness.
Study provides new clues to leukemia resurgence after chemotherapy
For the first time, researchers have discovered that some leukemia cells harvest energy resources from normal cells during chemotherapy, helping the cancer cells not only to survive, but actually thrive, after treatment.
Dialing up chemotherapy for pancreatic cancer with ultrasound
Researchers at Haukeland University Hospital in Bergen, Norway have combined a laboratory ultrasound technique called 'sonoporation' with the commercially-available chemotherapy compound Gemcitabine to increase the porosity of pancreatic cells with microbubbles and to help get the drug into cancer cells where it is needed.
Vitamin A may help improve pancreatic cancer chemotherapy
The addition of high doses of a form of vitamin A could help make chemotherapy more successful in treating pancreatic cancer, according to an early study by Queen Mary University of London.

Related Chemotherapy Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Changing The World
What does it take to change the world for the better? This hour, TED speakers explore ideas on activism—what motivates it, why it matters, and how each of us can make a difference. Guests include civil rights activist Ruby Sales, labor leader and civil rights activist Dolores Huerta, author Jeremy Heimans, "craftivist" Sarah Corbett, and designer and futurist Angela Oguntala.
Now Playing: Science for the People

#521 The Curious Life of Krill
Krill may be one of the most abundant forms of life on our planet... but it turns out we don't know that much about them. For a create that underpins a massive ocean ecosystem and lives in our oceans in massive numbers, they're surprisingly difficult to study. We sit down and shine some light on these underappreciated crustaceans with Stephen Nicol, Adjunct Professor at the University of Tasmania, Scientific Advisor to the Association of Responsible Krill Harvesting Companies, and author of the book "The Curious Life of Krill: A Conservation Story from the Bottom of the World".